Search
Cyclophosphamide Treatment Options
A collection of 2173 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
1393 - 1404 of 2173
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Combination Chemotherapy in Treating Patients With Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.
PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.
Gender:
ALL
Ages:
Between 15 years and 59 years
Trial Updated:
11/13/2018
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for intermediate-grade or immunoblastic non-Hodgkin's lymphoma.
PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have intermediate-grade or immunoblastic non-Hodg... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
11/13/2018
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas +2 locations
Conditions: Lymphoma
Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of different regimens of combination chemotherapy in treating patients with newly diagnosed mantle cell lymphoma.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
11/13/2018
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Withdrawn
This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride with asparaginase work in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/09/2018
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington
Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Recurrent T Lymphoblastic Leukemia/Lymphoma, Refractory B Lymphoblastic Lymphoma, Refractory T Lymphoblastic Lymphoma, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia
Completed
This randomized phase II trial studies how well giving busulfan, cyclophosphamide, and melphalan or busulfan and fludarabine phosphate before donor hematopoietic cell transplant works in treating younger patients with juvenile myelomonocytic leukemia. Giving chemotherapy before a donor hematopoietic transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the pat... Read More
Gender:
ALL
Ages:
Between 3 months and 18 years
Trial Updated:
11/09/2018
Locations: Children's Hospital of Alabama, Birmingham, Alabama +49 locations
Conditions: Juvenile Myelomonocytic Leukemia
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma
Completed
To determine the efficacy of high-dose topotecan, cyclophosphamide and melphalan in patients with Multiple Myeloma.
Gender:
ALL
Ages:
70 years and below
Trial Updated:
11/06/2018
Locations: U.T. M.D. Anderson Cancer Center, Houston, Texas
Conditions: Myeloma
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which treatment regi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/05/2018
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as pegfilgrastim, may increase the number of imm... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/31/2018
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Leukemia, Lymphoma
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.
PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.
Gender:
ALL
Ages:
Between 15 years and 55 years
Trial Updated:
10/24/2018
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Completed
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells are rejected by the body's normal tissues. Transplanting donated cells that have been treated with psoralen may prevent this from happening.
PURPOSE: Phase I trial to study the effectiveness of chemotherapy, radiation therapy, and psoralen-treated donor cells in treating patients who are underg... Read More
Gender:
ALL
Ages:
49 years and below
Trial Updated:
10/24/2018
Locations: University of Illinois at Chicago, Chicago, Illinois +2 locations
Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with chronic lymphocytic leukemia.
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
10/23/2018
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
Terminated
This is an open-label study to assess the safety, tolerability and efficacy of olaparib in combination with carboplatin. There are two parts in this study: Part A, a dose escalation in patients with advanced Human Epidermal Growth Factor 2 (HER-2) negative breast cancer and Part B, a dose expansion in the neoadjuvant treatment of HER-2 negative breast cancer patients with germline Breast Cancer Susceptibility Gene (BRCA)1/2 mutations.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
10/15/2018
Locations: Research Site, New York, New York +6 locations
Conditions: Breast Cancer
1393 - 1404 of 2173